| Background and Introduction

Derived from cell line and fragmented to mimic ctDNA, the GeneWell ctDNA MRD Panel Mix covers  common genes related to tumor-targeted therapy and contains 37 hotspot mutations. 4 gradients  of variant allele frequency, including 0%, 0.005%，0.05% and 0.5%, are accurately quantified by digital PCR to determine the limit of detection for MRD testing. In addition, the variants are further veri- fied by the Illumina TruSight™ Oncology 500 ctDNA panel for users' reference.

| Key Features

● 100% derived from  cell line, optimized  fragmentation  process to mimic  ctDNA

● 37 hotspot mutations,  covering common  genes related to  tumor-targeted  therapy

● High consistency  between NGS panel  and digital PCR 

● Gradient variant  allele frequency to  determine the limit  of detection for  MRD testing

● Manufactured in  ISO9001-certified  facility

| Product List